Edward A. Neuwelt

Edward A. Neuwelt

Auto-generated profile, based on publicly available information

Edward A. Neuwelt

Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2011 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
ENEdward A. Neuwelt
Edward A. Neuwelt
BBBjörn Bauer
Björn Bauer
CFChristoph Fahlke
Christoph Fahlke
Gert FrickerGert Fricker
Gert Fricker
CIConstantino Iadecola
Constantino Iadecola
LDLester R. Drewes
Lester R. Drewes

16 September 2009 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
JWJason S Weinstein
Jason S Weinstein
CVCsanad G Varallyay
Csanad G Varallyay
EDEdit Dosa
Edit Dosa
SGSeymur Gahramanov
Seymur Gahramanov
BHBronwyn Hamilton
Bronwyn Hamilton
ENEdward A Neuwelt
Edward A Neuwelt
Superparamagnetic iron oxide nanoparticles have diverse diagnostic and potential therapeutic applications in the central nervous system (CNS). They are useful as magnetic resonance imaging (MRI) contrast agents to evaluate: areas of blood–brain barrier (BBB) dysfunction related to tumors and other neuroinflammatory pathologies, the cerebrovasculature using perfusion-weighted MRI sequences, and in vivo cellular tracking in CNS disease or injury. Novel, targeted, nanoparticle synthesis strategies will allow for a rapidly expanding range of applications in patients with brain tumors, cerebral ischemia or stroke, carotid atherosclerosis, multiple sclerosis, traumatic brain injury, and epilepsy. These strategies may ultimately improve disease detection, therapeutic monitoring, and treatment efficacy especially in the context of antiangiogenic chemotherapy and antiinflammatory medications. The purpose of this review is to outline the current status of superparamagnetic iron oxide nanoparticles in the context of biomedical nanotechnology as they apply to diagnostic MRI and potential therapeutic applications in neurooncology and other CNS inflammatory conditions.

1 July 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PBPenelope R. Brock
Penelope R. Brock
KKKristin R. Knight
Kristin R. Knight
DFDavid R. Freyer
David R. Freyer
KCKathleen C.M. Campbell
Kathleen C.M. Campbell
PSPeter S. Steyger
Peter S. Steyger
ENEdward A. Neuwelt
Edward A. Neuwelt
Purpose: The platinum chemotherapy agents cisplatin and carboplatin are widely used in the treatment of adult and pediatric cancers. Cisplatin causes hearing loss in at least 60% of pediatric patients. Reducing cisplatin and high-dose carboplatin ototoxicity without reducing efficacy is important. Patients and Methods: This review summarizes recommendations made at the 42nd Congress of the International Society of Pediatric Oncology (SIOP) in Boston, October 21-24, 2010, reflecting input from international basic scientists, pediatric oncologists, otolaryngologists, oncology nurses, audiologists, and neurosurgeons to develop and advance research and clinical trials for otoprotection. Results: Platinum initially impairs hearing in the high frequencies and progresses to lower frequencies with increasing cumulative dose. Genes involved in drug transport, metabolism, and DNA repair regulate platinum toxicities. Otoprotection can be achieved by acting on several these pathways and generally involves antioxidant thiol agents. Otoprotection is a strategy being explored to decrease hearing loss while maintaining dose intensity or allowing dose escalation, but it has the potential to interfere with tumoricidal effects. Route of administration and optimal timing relative to platinum therapy are critical issues. In addition, international standards for grading and comparing ototoxicity are essential to the success of prospective pediatric trials aimed at reducing platinum-induced hearing loss. Conclusion: Collaborative prospective basic and clinical trial research is needed to reduce the incidence of irreversible platinum-induced hearing loss, and optimize cancer control. Wide use of the new internationally agreed-on SIOP Boston ototoxicity scale in current and future otoprotection trials should help facilitate this goal.

1 January 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HMHeather L. McConnell
Heather L. McConnell
CKCymon N. Kersch
Cymon N. Kersch
RWRandall L. Woltjer
Randall L. Woltjer
ENEdward A. Neuwelt
Edward A. Neuwelt
The mammalian brain is supplied with blood by specialized vasculature that is structurally and functionally distinct from that of the periphery. A defining feature of this vasculature is a physical blood-brain barrier (BBB). The BBB separates blood components from the brain microenvironment, regulating the entry and exit of ions, nutrients, macromolecules, and energy metabolites. Over the last two decades, physiological studies of cerebral blood flow dynamics have demonstrated that substantial intercellular communication occurs between cells of the vasculature and the neurons and glia that abut the vasculature. These findings suggest that the BBB does not function independently, but as a module within the greater context of a multicellular neurovascular unit (NVU) that includes neurons, astrocytes, pericytes, and microglia as well as the blood vessels themselves. Here, we describe the roles of these NVU components as well as how they act in concert to modify cerebrovascular function and permeability in health and in select diseases.

1 July 2017 in Kidney International
Verified
Journal Article
Closed access
GTGerda B. Toth
Gerda B. Toth
CVCsanad G. Varallyay
Csanad G. Varallyay
AHAndrea Horvath
Andrea Horvath
MBMustafa R. Bashir
Mustafa R. Bashir
PCPeter L. Choyke
Peter L. Choyke
ENEdward A. Neuwelt
Edward A. Neuwelt

17 October 2012 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
LMLeslie L Muldoon
Leslie L Muldoon
JAJorge I Alvarez
Jorge I Alvarez
DBDavid J Begley
David J Begley
RBRuben J Boado
Ruben J Boado
GZGregory J del Zoppo
Gregory J del Zoppo
ENEdward A Neuwelt
Edward A Neuwelt
The brain is in many ways an immunologically and pharmacologically privileged site. The blood–brain barrier (BBB) of the cerebrovascular endothelium and its participation in the complex structure of the neurovascular unit (NVU) restrict access of immune cells and immune mediators to the central nervous system (CNS). In pathologic conditions, very well-organized immunologic responses can develop within the CNS, raising important questions about the real nature and the intrinsic and extrinsic regulation of this immune privilege. We assess the interactions of immune cells and immune mediators with the BBB and NVU in neurologic disease, cerebrovascular disease, and intracerebral tumors. The goals of this review are to outline key scientific advances and the status of the science central to both the neuroinflammation and CNS barriers fields, and highlight the opportunities and priorities in advancing brain barriers research in the context of the larger immunology and neuroscience disciplines. This review article was developed from reports presented at the 2011 Annual Blood-Brain Barrier Consortium Meeting.